HIGHLIGHTS
- who: Wenxi Tang from the China ChinaUnited Arab Emirates University have published the paper: Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China, in the Journal: (JOURNAL)
- what: The aim of this costeffectiveness analysis was to compare camrelizumab plus chemotherapy with chemotherapy alone in advanced sqNSCLC from the perspective of the Chinese healthcare system. This study provides evidence of cost-effectiveness which may accelerate the process of listing in health insurance and promotion. The analysis showed that camrelizumab plus chemotherapy was unfavorable with a WTP thresholds lower . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.